诉讼背景 - 投资者因Revance Therapeutics公司涉嫌证券欺诈而提起集体诉讼 [1] - 诉讼涉及的时间范围为2024年2月29日至2024年12月6日 [3] 诉讼指控 - 公司未向投资者披露其违反分销协议的重大违约行为 [3] - 公司未披露违约行为导致的法律诉讼风险增加以及可能面临的财务和声誉损害 [3] - 公司未披露上述问题可能导致收购要约延迟或修改的风险 [3] - 公司在此期间对业务、运营和前景的积极陈述存在重大误导性或缺乏合理依据 [3] 投资者参与 - 受损失的投资者可在2025年3月4日前联系Howard G Smith律师事务所参与诉讼 [2] - 投资者可选择不采取行动，仍可作为缺席成员参与集体诉讼 [5]

公司背景与业务 - Revance是一家生物技术公司 专注于开发和商业化神经调节剂 用于美学和治疗领域 业务覆盖美国及国际市场 [3] - 公司与Teoxane SA签订了分销协议 获得Teoxane的Resilient Hyaluronic Acid®系列产品的独家分销权 包括RHA® Collection和RHA® Pipeline Products 协议涉及250万股Revance普通股及其他承诺 [4] 法律诉讼与指控 - 针对Revance及其高管提起集体诉讼 指控其在2024年2月29日至2024年12月6日期间违反联邦证券法 涉及虚假和误导性陈述 [1] - 诉讼指控公司未披露其违反与Teoxane的分销协议 导致诉讼风险增加 并可能影响与Crown的合并交易 [6] 合并交易与股价波动 - Revance与Crown Laboratories达成合并协议 Crown将以每股6.66美元的价格收购Revance所有流通股 总企业价值为9.24亿美元 [5] - 由于与Teoxane的纠纷 合并交易被推迟 最终Crown将收购价格下调至每股3.10美元 较原价下降超过50% [8] - 消息公布后 Revance股价在2024年9月23日下跌7.66% 至每股5.365美元 在2024年12月9日下跌20.68% 至每股3.03美元 [7][9] 市场反应与分析 - 市场分析师认为 收购价格大幅下调反映了Revance在Daxxify产品发布失败后的声誉损害 以及与Teoxane的合同纠纷 [9]

JOHNSON CITY, Tenn., Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance, at a price of $3.10 per Share in cash, without interest and less any applicable tax w ...

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=122002&from=4 CLASS PERIOD ...

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company. [CONTACT FORM] The lawsuit was filed on behalf of investors who acquired Revance ...

NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/revance-therapeutics ...

LOS ANGELES, Jan. 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=121491&from=4CLASS PERIOD: ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) in the United States District Court for the Middle District of Tennessee on behalf of all persons and entities who purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the “Class Period”) ...

SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.For more information, submit a form, email attorney Aar ...